Lenvatinib with standard treatment for MGMT-methylated glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding lenvatinib (a targeted drug that blocks blood vessel growth) to the standard temozolomide chemotherapy and radiation treatment improves outcomes for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylation). It aims to see if the combination can help people live longer without the cancer progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with glioblastoma (a type of brain cancer).
- Your tumor must test positive for a genetic marker called MGMT methylation.
- You must be between 18 and 75 years old.
- You must be able to perform daily activities with minimal assistance (Karnofsky score of at least 70%).
- Your liver and kidney function must be within normal limits.
- You must not have had chemotherapy or radiation for this brain tumor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
This trial tests adding lomustine chemotherapy to standard treatment for people with a specific type of glioblastoma that has a methylated MGMT gene. It aims to see if this combination helps control the tumor better and improves survival.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.